In 1996, US prescription pharmaceutical sales to pharmacies rose 10% tohit $85.35 billion, according to figures from IMS America, which noted that topping the list were antiulcer products and antidepressants.
The best-selling US prescription drug, with $1.76 billion in sales, was again Glaxo Wellcome's Zantac (ranitidine). Just behind this in the number two spot was Astra-Merck's antiulcerant Prilosec (omeprazole), with $1.74 billion in turnover, and in third place was Lilly's Prozac (fluoxetine) at $1.69 billion.
Sales of Amgen's Epogen (epoetin alfa) rose 23% to $1.18 billion, while those of Pfizer's Zoloft (sertraline) reached $1.1 billion last year, according to IMS figures.
This article is accessible to registered users, to continue reading please register for free. A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.
Login to your accountTry before you buy
7 day trial access
Become a subscriber
Or £77 per month
The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed
Chairman, Sanofi Aventis UK
Copyright © The Pharma Letter 2024 | Headless Content Management with Blaze